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Fibrinolytic parameters under ischemic stroke  
with diabetes mellitus combination
Abstract
Background: Fibrinolysis and thrombosis alterations include important 
parts of stroke pathophysiology. At the same time fibrinolytic system disorders 
are a common feature of patients with metabolic syndrome and diabetes. So 
it may increase the possibility of developing atherosclerotic lesions and oc-
clusive intravascular thrombi. The present study investigated the influence 
of type 2 diabetes mellitus presence on the indicators of fibrinolytic param-
eters (plasminogen activator inhibitor 1 (PAI-1), tissue-type plasminogen 
activator (tPA) content, streptokinase-activated plasminogen and α2-
antiplasmin activities, euglobulin clot lysis time (ECLT) and Hageman-
factor-dependent fibrinolysis time) under ischemic stroke (IS).
Materials and methods: Participants were 87 subjects with IS, 22 of 
them had diabetes mellitus. Blood samples besides for aforementioned pa-
rameters were analyzed for glucose and glycosylated haemoglobin content.
Results: The research established increase of plasma PAI-1 and tPA 
levels, ECLT, Hageman-factor-dependent fibrinolysis time in IS and IS with 
diabetes mellitus patient groups in comparison with the control. PAI-1 con-
centration in plasma was positively correlated with both lysis time tests but 
tPA content was negative correlated with glucose level and PAI-1 for only 
IS patients. But there was a high negative correlation between tPA and 
ECLT as well as Hageman-factor-dependent fibrinolysis time for both in-
vestigated IS forms.
Conclusions: The results showed important differences in the character-
istics of the fibrinolytic mechanism in IS patients compared with healthy 
population. The major differences were elevated PAI-1 and t-PA contents 
and prolonged ECLT in IS patients but no significant differences in these 
parameters were observed between the patients with IS and IS with diabetes.
INTRODUCTION
There are a lot of evidences of impaired fibrinolysis under metabolic syndrome as well as non-insulin-dependent (type 2) diabetes mel-
litus (DM) (1). Haemostasis abnormalities are usually associated with 
tissue-type plasminogen activator (tPA) - mediated conversion of pro-
enzyme plasminogen into active protease plasmin, which, in its turn, 
degrades fibrin structure of intravascular thrombi. Plasmin cleaves fibrin 
thus breaking down meshwork of clot and it is extremely short-lived due 
to inactivation by α2-antiplasmin (α2-AP), which is an abundant in-
hibitor restricting plasmin action (2).
In addition, it has been known for many years, that increased concen-
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activator inhibitor 1 (PAI-1), is also a concomitance of type 
2 diabetes (3). So, evolving evidence of the central role of 
PAI-1 and tPA in fibrinolysis and thrombosis mediating 
increasingly supports a theory that they are a significant 
risk factor for macrovascular complications and cardiovas-
cular diseases, particularly in patients with diabetes.
It should be noted, that abnormal endogenous fibrino-
lytic activity may also be a risk factor for such abundant 
cerebrovascular pathology as stroke. Both normal and 
high levels of PAI-1 have been observed in the acute phase 
of stroke (4). PAI-1 is a primary physiological inhibitor of 
endogenous fibrinolysis that acts via tPA inhibition, often 
leading to fibrin accumulation in basement membranes 
and interstitial tissues (5).
In view of the above tPA is a blood factor orchestrating 
the breakdown of blood clots. Therefore the US Food & 
Drug Administration approved it as the only thrombo-
lytic drug for treatment of patients with acute ischemic 
stroke (IS).
The other factor with crucial role in reducing plasmin 
activity and thus inhibiting fibrinolysis is a α2-antiplasmin. 
However, earlier studies of genetically deficient in either 
tPA, plasmin inhibitor, or α2-AP mice had paradoxically 
unexpected results (6). The removing profibrinolytic tPA 
or antifibrinolytic α2-AP had similar beneficial outcomes 
in a murine model of stroke. Other authors established 
higher concentration of plasmin-α2-AP complex in diabet-
ics (7). In addition, the fibrin network of plasma clots from 
patients with diabetes contains more plasmin-α2-AP than 
the fibrin network of plasma clots from control subjects (8).
Thus, despite the large amount of information about 
the important role of fibrinolytic system disorders under 
stroke, as well as diabetes, data characterising changes of 
mentioned parameters under conditions of IS with diabe-
tes mellitus combination lack. However, the important 
question about fibrinolytic system peculiarities under 
combination of pathologies remains unclear, especially in 
case of standard treatment such complicated deseases (9). 
So, the aim of the current study was to investigate possible 
differences in indicators of fibrinolytic parameters (PAI-1, 
tPA content, streptokinase-activated plasminogen and α2-
antiplasmin activities, euglobulin clot lysis time (ECLT) 
and Hageman-factor-dependent fibrinolysis time) under 
ischemic stroke with and without type 2 diabetes mellitus.
MATHERIALS AND METHODS
The experimental group included 87 patients (median 
age, 74.2 ± 9.0 years) with suspected IS were admitted to 
Kyiv city hospital #4 and 25 population controls (median 
age, 70.2 ± 10.3 years).
The diagnosis of IS was confirmed by neurovisualiza-
tion with computed tomography and magnetic resonance 
imaging of brain in all 87 patients, 22 (26.4%) of them 
had type 2 DM, diagnosed according to the World Health 
Organization guidelines (10).
All the patients underwent of PAI-1, tPA content, 
streptokinase-activated plasminogen and α2-antiplasmin 
activities, ECLT and Hageman-factor-dependent fibrino-
lysis time, glucose and glycosylated haemoglobin content 
and body mass index (BMI) measurements.
Patients were excluded if they had a past history of 
predisposition to hypercoagulability, coma, cancer, recent 
surgery or other estimated diseases.
This study was approved by the ethics committee of 
Educational and Scientific Centre Institute of Biology and 
Medicine of Taras Shevchenko National University of 
Kyiv (Ukraine) and performed in accordance with the 
ethical standards as laid down in the 1964 Declaration of 
Helsinki. Informed consent was obtained from all indi-
vidual participants included in the study.
All the patients had aspirin therapy in dose of 325 mg 
during the first 24 h in the hospital. Blood samples for 
haemostasis investigations were collected from the pa-
tients shortly after their admission to the hospital (acute 
phase of stroke) in tubes containing 1/10 volume of 0.129 
M sodium citrate. Venous fasting blood for DM identify-
ing was collected from the cubital vein in tubes with so-
dium citrate and K3EDTA from 8 to 9 am. 
Glucose content was estimated by enzymatic glucose 
oxidase method. 
PAI-1 and t-PA were measured by enzyme-linked im-
munosorbent assay.
Plasminogen and α2-antiplasmin plasma activities 
were estimated by chromogenic substrate S2251 cleavage 
with next spectrophotometry assay (11). Plasminogen ac-
tivation to plasmin was catalyzed by streptokinase. The 
incubation medium for plasminogen activity determina-
tion consisted of 0.05 M Tris-HCl buffer (pH 7.4), 25 μl 
of blood plasma; 3 mM S2251 substrate and 5-10 IU/ml of 
streptokinase. The volume of reaction medium was 250 
μl and the temperature was 37 °C. Absorption of released 
p-nitroaniline was measured in two-wave mode at 405 
nm and 492 nm with microplate spectrophotometer Syn-
ergy HT (BioTeck, USA).
The incubation medium for α2-AP activity assay con-
sisted of 0.05 M Tris-HCl buffer (pH 7.4), 25 μl of blood 
plasma, 3 mM S2251 substrate and 0.5 IU/ml of plasmin. 
Measurement of released p-nitroaniline absorption was 
performed as described above.
ECLT assay included two steps plasma euglobulin 
fraction obtainment and fibrinolytic analysis. 200 μl of 
chilled plasma were placed in a glass centrifuge tube with 
1.8 ml of cold distilled H2O and 150 μl of 0.25% acetic 
acid. The mixture was gently stirred and incubated for 30 
min at 4 °C. The precipitate was consisted of plasma eu-
globulin reach fraction that contained plasminogen, plas-
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minogen activators (primarily tPA) and fibrinogen. The 
supernatant was discarded after centrifugation at 700 g 
for 15 min at 4 °C and the precipitate was dissolved in 250 
μl of 0.05 M Tris-HCl buffer (pH 7.4).
Total fibrinolytic activity was determined by the time 
of fibrin clot lysis by euglobulin fractions. Clots were 
formed by CaCl2 solution adding and polymerization of 
fibrin from euglobulin factions. 0.1 ml of 25 mM CaCl2 
was added to 250 μl of obtained euglobulin fractions dis-
solved in 0.05 M Tris-HCl buffer (pH 7.4). Samples were 
incubated at 37 °C and time of complete clot lysis (in 
hours) was determined (12). 
Hageman-factor-dependent fibrinolysis time was de-
tected after kaolin-stimulated coagulation precipitate 
obtainment (12). 0.5 ml of plasma was mixed with 8 ml 
of distilled H2O, 0.2 ml of 1% solution of acetic acid and 
0.5 ml of 0.5% kaolin suspension in plastic tubes. The 
mix ture was gently stirred and incubated at 37 °C for 30 
min with next centrifugation for 6 min at 700 g. The 
supernatant was discarded and the residue was dissolved 
in 0.5 ml of 0.05 M Tris-HCl buffer (pH 7.4). After in-
duced by 25 mM CaCl2 (in equal volume) clot formation 
time (in minutes) of its complete lysis was determined.
Glycosylated hemoglobin was assayed with HbA1c 
IMU-LA-TEST (Erba Lachema s.r.o., CzechRepublic).
BMI as an index of obesity extent was calculated as 
body weight (kg) divided by square of height (m2).
The results were statistically analysed by Statistica 7.0 
(StatSoftInc., USA) and presented as median with quar-
tilies for all numerical variables, minimum value of sta-
tistical series (min) and maximum value of statistical se-
ries (max). Distribution within groups was assessed using 
the Shapiro-Wilk test. Because of the fact that test vari-
ables were not normally distributed, further analysis by 
non-parametric tests was performed. The Mann-Whitney 
U-test was used to compare differences between studied 
and control groups. Correlations between variables were 
assessed using Spearman’s rank correlation coefficient. All 
statistical tests were 2-tailed with p-values <0.05 taken as 
significant.
RESULTS
There were no statistically significant differences noted 
between the groups of IS patients with or without DM in 
age and sex. BMI was significantly higher under IS with 
DM (20.26 vs. 34.01, p=0.02).
The group of patients with IS+DM included individu-
als, whose mean indicator of blood glucose was 9.47±2.65 
mmol/L, while in the group with IS this parameter was 
4.93±0.97 mmol/L. 
The research has established the statistically significant 
changes of PAI-1 and tPA levels in both investigated pa-
tient groups in comparison with the control (Figure 1). 
PAI-1 concentration in plasma of the patients with IS only 
was significantly higher compared to the control group 
(0.093 vs. 0.033, p<0.001). This index was increased in 
the patients with IS complicated by DM relatively the 
control values as well (0.092 vs. 0.033, p<0.001) but no 
significant differences (p=0.51) in plasma PAI-1 contents 
were observed between the patients with IS and IS with 
diabetes. It should be noted for IS 95% CI 0.101-0.121 
and for IS+DM 95% CI 0.085-0.116 were estimated, so 
more pronounced deviations of PAI-1 content compared 
with the control were observed under IS without DM.
There was no a significant correlation between plasma 
PAI-1 and any investigated blood parameters of patients 
with IS+DM. However, plasma PAI-1 positively corre-
lated with both lysis time tests of patients with IS alone. 
The established Spearman’s rank correlation coefficient 
for PAI-1 and ECLT was r=0.393; p=0.0004, this param-
eter for PAI-1 and Hageman-factor-dependent fibrinolysis 
Figure 1. Plasminogen activator inhibitor-1 plasma content under 
ischemic stroke and ischemic stroke with diabetes mellitus. (r.u. – 
relative units)
* - The result is significant at p<0.05 in comparison with the control
Figure 2. Tissue-type plasminogen activator plasma content under 
ischemic stroke and ischemic stroke with diabetes mellitus. (r.u. – 
relative units)
* - The result is significant at p<0.05 in comparison with the control
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time was 0.364; p=0.003. We also found not so signifi-
cant but negative correlation between plasma PAI-1 and 
tPA level in the patients with IS (r=–0.249; p=0.028).
The tPA plasma content investigation revealed increase 
of this parameter under the both IS conditions (Figure 
2). The median of tPA concentrations of IS patient group 
(n=65) did not differ from IS+DM group (n=22) (0.046 
versus 0.048 r.u). But tPA levels were more than two times 
higher in both IS and IS+DM groups in comparison with 
the control subjects (n=25; 0.023 r.u).
We have found the negative correlation of plasma 
tPA content with glucose level and PAI-1 for IS patients 
(r=–0.26; p=0.022 and r=–0.249; p=0.028, respectively). 
There was no significant correlation of these parameters 
in the case of IS with type 2 DM. But it was high negative 
correlation between tPA and ECLT as well as Hageman-
factor-dependent fibrinolysis time for both investigated 
IS forms. Spearman rank order correlation for tPA and 
ECLT was –0.65 under IS and -0.56 under IS with DM 
(p<0.001) (Table 1).
As it could be seen from the Figure 3 and Figure 4, 
the aforementioned parameters were significantly pro-
longed. So Hageman-factor-dependent fibrinolysis time 
was more than threefold higher for both diabetic (21 
min; 95% CI 20.85–22.73) and non-diabetic (22 min; 
95% CI 21.7–22.98) patients with IS compared with 
Table 1. Spearman rank order correlation of fibrinolytic parameters and glucose content in groups of ischemic stroke and ischemic stroke compli-
cated by diabetes mellitus.
Ischemic stroke Ischemic stroke + Diabetes mellitus
Spearman Rank 
Order Correlation (r)
p Spearman Rank 
Order Correlation (r)
p
PAI-1 & tPA -0.249737 0.028494* 0.133188 0.459962
PAI-1 & ECLT 0.392519 0.000414* 0.079920 0.658407
PAI-1 & Hageman-dependent fibrinolysis time 0.332444 0.003137* 0.255439 0.151363
tPA & ECLT -0.646481 0.000000* -0.565201 0.000610*
tPA & Hageman-dependent fibrinolysis time -0.578119 0.000000* -0.492712 0.003579*
Hageman-dependent fibrinolysis time & ECLT 0.776947 0.000000* 0.799899 0.000000*
α2-AP & ECLT -0.152304 0.186058 -0.348789 0.046663*
α2-AP & Hageman-dependent fibrinolysis time -0.084503 0.464966 -0.410659 0.017602*
Glucose & PAI-1 0.246195 0.030900* -0.180958 0.313554
Glucose & tPA -0.260160 0.022309* 0.187725 0.295490
Glucose & α2-AP 0.284286 0.012220* 0.149967 0.404843
* - p<0.05
Figure 3. Hageman-factor-dependent fibrinolysis time under isch-
emic stroke and ischemic stroke with diabetes mellitus.
* - The result is significant at p<0.05 in comparison with the control
Figure 4. Euglobulin clot lysis time under ischemic stroke and isch-
emic stroke with diabetes mellitus.
* - The result is significant at p<0.05 in comparison with the control
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relatively healthy control donors (7 min; 95% CI 6.74–
7.87) indexes.
The other fibrinolysis time parameter ECLT had even 
more pronounced deviations. Its value was 1.5±0.2 h for 
the control group but there were 7.77±0.7 h for the IS 
patients and 7.64±0.73 h in the case of IS with diabetes. 
So statistically significant diversities of Hageman-factor-
dependent fibrinolysis time and euglobulin clot lysis time 
between the control and IS patients (p<0.01) were estab-
lished and no differences between presence of hypergly-
cemia under IS or its absence were observed.
The Spearman rank order correlation revealed the 
strong correlation not only for tPA content with fibrino-
lysis time tests (ECLT and Hageman-factor-dependent 
fibrinolysis time) but also the high level of positive cor-
relation exactly between ECLT and Hageman-factor-
dependent fibrinolysis time (r=0.79 for IS+DM; r=0.78 for 
IS p<0.001) independently of diabetes presence under 
stroke. Thus, despite the identical trend of PAI-1 content 
changes and prolongation of time lysis tests in patients 
with IS and stroke complicated by DM, in the latter case, 
there was no correlation between PAI-1 content and 
ECLT, which was observed under IS alone. However, 
ischemic stroke with diabetes mellitus was characterized 
by negative correlation in both time lysis parameters with 
α2-antiplasmin activity (Table 1). This parameter was 
lower in both pathological conditions and amounted 
80–85% compared with the control (Figure 5). 
It should be noted that IS patients without hypergly-
cemia manifested statistically significant correlation of 
glucose level with PAI-1, tPA content and α2-AP activity 
(Table 1), that wasn’t observed under stroke with DM.
As the quantity of tPA was increased in stroke groups 
and main substrate of this secreted serine protease is gly-
coprotein plasminogen (PLG), which is synthesized in 
liver and circulates in blood, to assay streptokinase stimu-
lated blood circulating PLG activity seems to be relevant. 
So the general tendency to some decrease of PLG activity 
under IS similarly like under IS+DM was shown (Figure 
6). The median of PLG activity of IS patients fluctuated 
near 87.3% compared with the parameter from relatively 
healthy donors, this activated fibrinolytic potential 
amounted 87.2% of the control data in the case of diabe-
tes mellitus stroke. It should be noted that this parameter 
didn’t correlate with any of the investigated criteria nei-
ther under the stroke nor under the stroke with glycemic 
conditions.
Plasmin, which is generated from plasminogen, cleaves 
fibrin, thus breaking down meshwork of clot and is ex-
tremely short-lived due to α2-antiplasminin activation (2). 
The α2-AP activity was shown to be some depleted under 
both investigated IS conditions compared with the con-
trol. The median value was almost similar for stroke and 
stroke with diabetes. But significantly more pronounced 
fluctuations of indicators were observed under the stroke 
only. In addition, α2-AP activity positively correlated with 
glucose level under stroke but not under DM, and nega-
tively correlated with both time lysis parameters (Hage-
man-factor-dependent fibrinolysis time and euglobulin 
clot lysis time) in the case of hyperglycemia presence un-
der stroke.
DISCUSSION
It was established that the main markers of fibrinolysis 
had significant changes in the patients with acute isch-
emic stroke and such disturbances were independent of 
type 2 diabetes mellitus presence. Thus, plasma quantity 
of PAI-1 increased almost threefold under acute stroke 
compared with the control group and there was the ear-
lier study describing the elevated level of PAI-1 under IS 
(4). PAI-1 indicator of patients under stroke with diabetes 
was similar and these data coincided with a huge number 
Figure 5. α2-Antiplasmin plasma activity under ischemic stroke and 
ischemic stroke with diabetes mellitus
* - The result is significant at p<0.05 in comparison with the control
Figure 6. Plasminogen plasma activity under ischemic stroke and 
ischemic stroke with diabetes mellitus.
* - The result is significant at p<0.05 in comparison with the control
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of fibrinolysis investigations under metabolic syndrome 
(13, 14), obesity (15) as well diabetes mellitus (16). Also 
PAI-1 and antithrombin III inhibiting fibrinolysis, con-
sistently have been found to be elevated in diabetic pa-
tients and in those with insulin resistance. Additionally, 
there were both cross-sectional and prospective studies 
showing that increased tPA antigen and PAI-1 levels have 
been significantly associated with IS (17). PAI-1, which 
abnormal high quantity was shown under stroke, is the 
most efficient inhibitor of tPA in plasma and the majority 
of circulating tPA is bound with this inhibitor. In the 
present report, we documented that tPA level was abnor-
mally high in subjects with both conditions of acute IS as 
well. Our findings coincided with previous studies, show-
ing that high tPA antigen levels can be detected in the 
same group of individuals, who were examined in either 
acute or subacute phase after stroke (18). It should be 
noted that recombinant tissue plasminogen activator 
treatment has long been the only available therapeutic 
agent for IS (2). Moreover recent study has found a de-
creased recanalization rate following recombinant tPA 
administration in the presence of hyperglycemia (17). E. 
C. van Overbeek et al. found that higher baseline plasma 
tPA-activity (but not PAI-1 level) was associated with 
progression of white matter hyperintensities after 2 years 
of follow-up in lacunar stroke patients (19).
The interaction between tPA and PAI-1 and their co-
ordinated appearance in plasma are highly complex. Total 
amount of tPA and PAI-1 antigens in plasma usually 
shows a strong positive correlation, suggesting that syn-
thesis and/or clearance of tPA and PAI-1 are biologically 
linked. However, an increased tPA production due to 
increased PAI-1 levels does not automatically result in 
increased amount of active tPA. Instead of that, tPA activ-
ity reveals a negative correlation with both PAI-1 and tPA 
antigen. This latter correlation may seem confusing, since 
increase in total amount of tPA results in tPA activity 
decrease. In other words, high tPA antigen concentration 
in stroke patients may indicate inactivation of fibrino-
lytic system or may be due to a delayed clearance of com-
plexed with inhibitors tPA. High PAI-1 antigen concen-
trations represent increased fibrinolytic inhibition in 
patients with cerebral infarction (4).
The results of this investigation revealed significant 
reduction of fibrinolysis that was concluded from extend 
euglobulin clot lysis time as well as Hageman-dependent 
fibrinolysis time. Corresponding changes of ECLT un-
der stroke were also described by (20). The literature data 
in the case of diabetes mellitus are not so single-valued, 
so a prolonged ECLT may occure due to diabetes (21). 
But it was showed ECLT activation under type 1 DM 
(203.4+/–76.8 min vs. in the control group 276.08+/–
84.87 min, p < 0.05) and conversely a reduction of eu-
globulin fibrinolysis under type 2 DM (448+/–117 min) 
compared with the control (p<0.05) (22). Moreover there 
were authors, who postulated the highest PAI correlation 
with ECLT (23), which was also established in this inves-
tigation but only under IS. The literature data of Hage-
man-factor-dependent fibrinolysis time were quite rare 
under the studied pathologic state.
Tissue-type plasminogen activators, dramatically in-
creasing in quantity under stroke, mediate conversion of 
plasminogen to active protease plasmin. Maybe such ex-
cessive changes of tPA level led to depletion of plasmino-
gen activity pool under ischemic stroke, which, in its turn, 
would have negative consequences for fibrinolysis. Similar 
results (24) showed lower mean of plasminogen activity 
in total cerebral infarction group and in patients with 
cardioembolic stroke, compared with the control. Al-
though it is well known that glycation of plasminogen in 
diabetes directly affects fibrinolysis by decreasing plasmin 
generation and reducing protein-specific activity, we 
haven’t revealed any difference between stroke patients 
with or without diabetes mellitus. The same, independent 
of glycaemia presence, changes were indicated for α2-
antiplasmin activity.
The obtained results showed that there were important 
differences in the characteristics of the fibrinolytic mecha-
nism in ischemic stroke patients compared with healthy 
population. The major differences were prolonged euglob-
ulin clot lysis time and elevated PAI-1 and t-PA contents 
in ischemic stroke patients. In addition, there were not any 
significant differences in deviations of aforementioned fi-
brinolytic parameters under ischemic stroke complicated 
by type 2 diabetes mellitus in comparison with ischemic 
stroke but it was found changes of Spearman rank order 
correlation between PAI-1 & tPA, PAI-1 & ECLT, Glu-
cose & PAI-1, Glucose & tPA in case of the diabetes. These 
findings support the hypothesis that fibrinolysis distur-
bances are accompanied cerebrovascular events.
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